Compare YUM & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUM | EW |
|---|---|---|
| Founded | 1997 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 45.5B |
| IPO Year | 1997 | 2000 |
| Metric | YUM | EW |
|---|---|---|
| Price | $145.09 | $86.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | ★ $163.00 | $94.68 |
| AVG Volume (30 Days) | 2.1M | ★ 3.5M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.13 | 2.33 |
| Revenue | ★ $8,061,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $9.13 | $14.26 |
| Revenue Next Year | $9.53 | $9.77 |
| P/E Ratio | ★ $28.24 | $37.70 |
| Revenue Growth | ★ 11.60 | 10.60 |
| 52 Week Low | $122.13 | $65.94 |
| 52 Week High | $163.30 | $87.89 |
| Indicator | YUM | EW |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 59.20 |
| Support Level | $146.94 | $83.60 |
| Resistance Level | $155.23 | $87.40 |
| Average True Range (ATR) | 2.51 | 1.76 |
| MACD | -0.76 | -0.28 |
| Stochastic Oscillator | 0.87 | 63.57 |
Yum Brands is a US-based restaurant operator featuring a portfolio of four brands: KFC (31,981 global units at year-end 2024), Pizza Hut (20,225 units), Taco Bell (8,757 units), and Habit Burger & Grill (nearly 400 units). With more than $65 billion in 2024 systemwide sales, the firm is the second-largest restaurant company in the world behind McDonald's ($131 billion). Yum is 98% franchised, with the largest franchisee, Yum China, spun out in 2016, after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity. Yum is the newest evolution of Tricon, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.